The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
Summarize recent treatment advances in paroxysmal nocturnal hemoglobinuria and describe how complement inhibitors fit into management strategies.
Critically evaluate treatment strategies for patients with low-risk and high-risk myelodysplastic syndromes.
Describe how the scientific understanding of molecular advances in Ph-negative chronic myeloproliferative neoplasms has had an impact on management strategies.
Summarize the role of germline predisposition to myeloid malignancies and its impact on treatment strategies.
List the recent treatment advances for acute myeloid leukemia in older patients, detail their mode of action and safety and efficacy profiles, and define their use in clinical management strategies.
Summarize the challenges in assessing transplant feasibility and current transplant strategies in older MDS patients.
Designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS, AML and myeloid malignancies. In addition, members of patient advocacy groups will benefit from this education.
Bhumika Patel, MD
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Sudipto Mukherjee, MD, PhD, MPH
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.